Literature DB >> 23764634

Preparing for the unexpected: the pivotal role of social and behavioral sciences in trials of biomedical HIV prevention interventions.

Beryl A Koblin1, Michele Andrasik, Judy Austin.   

Abstract

A range of efficacies have been reported for biomedical HIV prevention interventions, including antiretroviral treatment, male circumcision, preexposure prophylaxis, microbicides, and preventive vaccines. This range of efficacies probably results from the influence of multiple inputs and processes during trials, including the strength and target of the intervention, host factors, target population characteristics, level of HIV exposure, and intervention dose. Expertise in social and behavioral sciences, in conjunction with basic science, clinical research, epidemiology, biostatistics, and community, is needed to understand the influence of these inputs and processes on intervention efficacy, improve trial design and implementation, and enable interpretation of trial results. In particular, social and behavioral sciences provide the means for investigating and identifying populations suitable for recruitment into and retention in trials and for developing and improving measures of HIV exposure and intervention dose, all within the larger sociocultural context. Integration of social and behavioral sciences early in idea generation and study design is imperative for the successful conduct of biomedical trials and for ensuring optimal data collection approaches necessary for the interpretation of findings, particularly in cases of unexpected results.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23764634      PMCID: PMC3737568          DOI: 10.1097/QAI.0b013e31829a3a4d

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  39 in total

1.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

2.  Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.

Authors:  Ronald H Gray; Godfrey Kigozi; David Serwadda; Frederick Makumbi; Stephen Watya; Fred Nalugoda; Noah Kiwanuka; Lawrence H Moulton; Mohammad A Chaudhary; Michael Z Chen; Nelson K Sewankambo; Fred Wabwire-Mangen; Melanie C Bacon; Carolyn F M Williams; Pius Opendi; Steven J Reynolds; Oliver Laeyendecker; Thomas C Quinn; Maria J Wawer
Journal:  Lancet       Date:  2007-02-24       Impact factor: 79.321

3.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

4.  Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.

Authors:  Robert C Bailey; Stephen Moses; Corette B Parker; Kawango Agot; Ian Maclean; John N Krieger; Carolyn F M Williams; Richard T Campbell; Jeckoniah O Ndinya-Achola
Journal:  Lancet       Date:  2007-02-24       Impact factor: 79.321

5.  HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial.

Authors:  Bradford N Bartholow; Susan Buchbinder; Connie Celum; Vamshidar Goli; Beryl Koblin; Michael Para; Michael Marmor; Richard M Novak; Kenneth Mayer; Catherine Creticos; Patti Orozco-Cronin; Vladimir Popovic; Timothy D Mastro
Journal:  J Acquir Immune Defic Syndr       Date:  2005-05-01       Impact factor: 3.731

6.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.

Authors:  Gita Ramjee; Saidi Kapiga; Stephen Weiss; Leigh Peterson; Corey Leburg; Cliff Kelly; Benoît Masse
Journal:  J Acquir Immune Defic Syndr       Date:  2008-01-01       Impact factor: 3.731

7.  Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa.

Authors:  Keren Middelkoop; Landon Myer; Daniella Mark; Sibonisile P Mthimunye; Joalida Smit; Robin Wood; Linda-Gail Bekker
Journal:  J Adolesc Health       Date:  2008-03-06       Impact factor: 5.012

8.  The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials.

Authors:  Gaston Djomand; Barbara Metch; Carmen D Zorrilla; Yeycy Donastorg; Martin Casapia; Tonya Villafana; Jean Pape; Peter Figueroa; Marianne Hansen; Susan Buchbinder; Chris Beyrer
Journal:  J Acquir Immune Defic Syndr       Date:  2008-05-01       Impact factor: 3.731

9.  SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.

Authors:  Paul J Feldblum; Adesina Adeiga; Rashidi Bakare; Silver Wevill; Anja Lendvay; Fatimah Obadaki; M Onikepe Olayemi; Lily Wang; Kavita Nanda; Wes Rountree
Journal:  PLoS One       Date:  2008-01-23       Impact factor: 3.240

10.  SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana.

Authors:  Leigh Peterson; Kavita Nanda; Baafuor Kofi Opoku; William Kwabena Ampofo; Margaret Owusu-Amoako; Andrew Yiadom Boakye; Wes Rountree; Amanda Troxler; Rosalie Dominik; Ronald Roddy; Laneta Dorflinger
Journal:  PLoS One       Date:  2007-12-19       Impact factor: 3.240

View more
  13 in total

Review 1.  Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities.

Authors:  Kathrine Meyers; Sarit A Golub
Journal:  Curr Opin HIV AIDS       Date:  2015-07       Impact factor: 4.283

2.  Moving the bar to the right place: positioning interventions in HIV prevention.

Authors:  Beryl A Koblin; Gordon Mansergh; Margaret Chesney; Thomas Coates
Journal:  AIDS Behav       Date:  2014-04

3.  Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions.

Authors:  Alexandra M Minnis; Ariane van der Straten; Parichat Salee; Craig W Hendrix
Journal:  AIDS Behav       Date:  2016-07

4.  Individual and community factors associated with geographic clusters of poor HIV care retention and poor viral suppression.

Authors:  Michael G Eberhart; Baligh R Yehia; Amy Hillier; Chelsea D Voytek; Danielle J Fiore; Michael Blank; Ian Frank; David S Metzger; Kathleen A Brady
Journal:  J Acquir Immune Defic Syndr       Date:  2015-05-01       Impact factor: 3.731

Review 5.  Lessons learned from HIV vaccine clinical efficacy trials.

Authors:  Tracey A Day; James G Kublin
Journal:  Curr HIV Res       Date:  2013-09       Impact factor: 1.581

6.  Transgender Women's Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs).

Authors:  Christine Tagliaferri Rael; Michelle Martinez; Rebecca Giguere; Walter Bockting; Caitlin MacCrate; Will Mellman; Pablo Valente; George J Greene; Susan G Sherman; Katherine H A Footer; Richard T D'Aquila; Alex Carballo-Diéguez; Thomas J Hope
Journal:  AIDS Behav       Date:  2020-05

7.  HIV self-testing among key populations: an implementation science approach to evaluating self-testing.

Authors:  Joseph D Tucker; Chongyi Wei; Razia Pendse; Ying-Ru Lo
Journal:  J Virus Erad       Date:  2015-01

8.  Recruitment of Underrepresented Minority Researchers into HIV Prevention Research: The HIV Prevention Trials Network Scholars Program.

Authors:  Sten H Vermund; Erica L Hamilton; Sam B Griffith; Larissa Jennings; Typhanye V Dyer; Kenneth Mayer; Darrell Wheeler
Journal:  AIDS Res Hum Retroviruses       Date:  2017-12-20       Impact factor: 2.205

9.  Efficacy of a Small-Group Intervention for Post-Incarcerated Black Men Who Have Sex with Men and Women (MSMW).

Authors:  Nina T Harawa; Heather Guentzel-Frank; William Jason McCuller; John K Williams; Gregorio Millet; Lisa Belcher; Heather A Joseph; Ricky N Bluthenthal
Journal:  J Urban Health       Date:  2018-04       Impact factor: 5.801

10.  Learning from the private sector: towards a keener understanding of the end-user for microbicide introduction planning.

Authors:  Amy H Lin; Tiffany L Breger; Matthew Barnhart; Ann Kim; Charlotte Vangsgaard; Emily Harris
Journal:  J Int AIDS Soc       Date:  2014-09-08       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.